Benefit-Risk Assessment Based on Ordered Clinical Outcomes

被引：0
|
作者：
Caster, Ola [1 ,2 ]
Noren, G. Niklas [1 ]
Ekenberg, Love [2 ]
Edwards, I. Ralph [1 ]
机构：
[1] WHO Collaborating Ctr Int Drug Monitoring, Uppsala, Sweden
[2] Stockholm Univ, Dept Comp & Syst Sci, Stockholm, Sweden
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2010年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
17
引用
下载
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [21] Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
    Sumithran, Priya
    Proietto, Joseph
    DRUG SAFETY, 2014, 37 (08) : 597 - 608
  • [22] Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessment
    Tervonen, Tommi
    Prawitz, Thibaud
    Chua, Gin Nie
    Hyacinthe, Johanna
    Pinto, Cathy Anne
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2022, 144 : 1 - +
  • [23] A Benefit-Risk Assessment of Basiliximab in Renal Transplantation
    Ugo Boggi
    Romano Danesi
    Fabio Vistoli
    Marco Del Chiaro
    Stefano Signori
    Piero Marchetti
    Mario Del Tacca
    Franco Mosca
    Drug Safety, 2004, 27 : 91 - 106
  • [24] Benefit-risk assessment of vitamin D supplementation
    Bischoff-Ferrari, H. A.
    Shao, A.
    Dawson-Hughes, B.
    Hathcock, J.
    Giovannucci, E.
    Willett, W. C.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 (07) : 1121 - 1132
  • [25] A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
    Enzo Nisoli
    Michele O. Carruba
    Drug Safety, 2003, 26 : 1027 - 1048
  • [26] A benefit-risk assessment of sibutramine in the management of obesity
    Nisoli, E
    Carruba, MO
    DRUG SAFETY, 2003, 26 (14) : 1027 - 1048
  • [27] Benefit-risk assessment: to quantify or not to quantify, that is the question
    Yuan, Zhong
    Levitan, Bennett
    Berlin, Jesse A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (06) : 653 - 656
  • [28] Benefit-risk assessment of raloxifene in postmenopausal osteoporosis
    Cranney, A
    Adachi, JD
    DRUG SAFETY, 2005, 28 (08) : 721 - 730
  • [29] On a Stepwise Quantitative Approach for Benefit-Risk Assessment
    Weili He
    Yaxuan Sun
    Qing Li
    Sabrina Wan
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 625 - 634
  • [30] Benefit-risk assessment: industry and regulatory perspectives
    Reactions Weekly, 2001, 882 (1) : 3 - 4
12345